Contact : Mr.Thyen
Email us at firstname.lastname@example.org
Whatsapp : +86 180 3817 6818
Cas No: 827033-10-3
Sequence:H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2 acetate salt
Appearance: white powder
Also know as Lyxumia,ZP10A peptide, AQVE-10010,ZP10,DesPro36Exendin-4(1-39)-Lys6-NH2
Lixisenatide (trade name Lyxumia in the Europe and Adlyxin in the U.S.) is a once-daily injectable GLP-1 receptor agonist for the treatment of diabetes type II.
Lyxumia is injected once daily subcutaneously (under the skin) in areas including the upper arm, abdomen or thigh. It should be injected in the hour before the first or last meal of the day.
It comes in a solution that is usually prescribed at a starting dose of 10 micrograms once a day. This is then increased to 20 micrograms once a day after 14 days.
You should not take two injections on the same day. If you forget your normal injection, take it in the hour before your next meal.
Lyxumia is for people with type 2 diabetes whose blood sugar is not controlled by long-acting insulin or oral antidiabetic medication – such as metformin, sulfonylureas or glinides – alongside diet and exercise.
Lyxumia is not to be used in people with type 1 diabetes, or people who are pregnant, breastfeeding, under 18, receiving dialysis or have severe kidney failure.
The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial found that lixisenatide provided a modest benefit in terms of weight gain for patients. This is because Lyxumia and other GLP-1 agonists help with weight loss mainly by decreasing appetite.
Weight loss is an important aspect of treatment for people with type 2 diabetes.